Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 17, 2012

Primary Completion Date

April 7, 2016

Study Completion Date

August 30, 2016

Conditions
Recurrent/Refractory CNSIntraocular Lymphoma
Interventions
DRUG

Lenalidomide

"Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral"

DRUG

Rituximab

"Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)"

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

James Rubenstein

OTHER